Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday.

Other analysts have also recently issued research reports about the stock. Piper Jaffray Companies reissued an “overweight” rating on shares of Oxford Immunotec Global in a research note on Sunday, November 11th. ValuEngine raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating in a research note on Wednesday, September 12th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.67.

OXFD opened at $15.01 on Wednesday. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.19.

Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings results on Friday, November 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The company had revenue of $16.10 million for the quarter, compared to analyst estimates of $33.60 million. During the same quarter last year, the company earned ($0.70) EPS. The firm’s revenue for the quarter was up 7.3% on a year-over-year basis. As a group, equities research analysts expect that Oxford Immunotec Global will post -1.09 earnings per share for the current fiscal year.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $15.50, for a total transaction of $46,500.00. Following the sale, the director now directly owns 9,000 shares in the company, valued at approximately $139,500. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Peter Wrighton-Smith sold 86,100 shares of the stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the sale, the chief executive officer now owns 539,569 shares in the company, valued at $9,938,860.98. The disclosure for this sale can be found here. Insiders have sold a total of 109,100 shares of company stock valued at $1,966,662 in the last ninety days. 6.61% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in OXFD. Bank of Montreal Can acquired a new stake in shares of Oxford Immunotec Global in the 2nd quarter valued at $132,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Oxford Immunotec Global in the 2nd quarter valued at $333,000. Wasatch Advisors Inc. raised its holdings in shares of Oxford Immunotec Global by 18.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 883,761 shares of the company’s stock valued at $11,392,000 after purchasing an additional 138,571 shares in the last quarter. C WorldWide Group Holding A S raised its holdings in shares of Oxford Immunotec Global by 25.2% in the 2nd quarter. C WorldWide Group Holding A S now owns 164,073 shares of the company’s stock valued at $2,115,000 after purchasing an additional 33,059 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Oxford Immunotec Global by 45.8% in the 2nd quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock valued at $424,000 after purchasing an additional 10,320 shares in the last quarter. Institutional investors and hedge funds own 90.94% of the company’s stock.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Story: How can you know how many shares are floating?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.